RELMADA THERAPEUTICS, INC. Proceeds from Issuance or Sale of Equity
RELMADA THERAPEUTICS, INC. (RLMD) reported Proceeds from Issuance or Sale of Equity of $19.79 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2021-05-12
- RELMADA THERAPEUTICS, INC. proceeds from issuance or sale of equity for the quarter ending 2021-03-31 was $19.79M.
- RELMADA THERAPEUTICS, INC. proceeds from issuance or sale of equity for the quarter ending 2019-06-30 was $10.86M.
- RELMADA THERAPEUTICS, INC. proceeds from issuance or sale of equity for the quarter ending 2019-03-31 was $1.73M.
- RELMADA THERAPEUTICS, INC. proceeds from issuance or sale of equity for the quarter ending 2018-12-31 was $4.77M.
- RELMADA THERAPEUTICS, INC. proceeds from issuance or sale of equity for fiscal 2020 was $19.79M.
- RELMADA THERAPEUTICS, INC. proceeds from issuance or sale of equity for fiscal 2019 was $17.76M.
| Period end | Proceeds from Issuance or Sale of Equity 3 month | Proceeds from Issuance or Sale of Equity 6 month | Proceeds from Issuance or Sale of Equity 9 month | Proceeds from Issuance or Sale of Equity 12 month |
|---|---|---|---|---|
| 2021-03-31 | $19.79M 10-Q · filed 2021-05-12 | |||
| 2020-12-31 | $19.79M 10-K · filed 2021-03-24 | |||
| 2019-12-31 | $109.45M 10-KT · filed 2020-03-26 | |||
| 2019-06-30 | $10.86M derived: 10-KT 12 month − 10-Q 9 month · filed 2020-03-26 | $12.58M derived: sum of 2 quarters · filed 2020-03-26 | $17.36M derived: sum of 3 quarters · filed 2020-03-26 | $17.76M 10-KT · filed 2020-03-26 |
| 2019-03-31 | $1.73M derived: 10-Q 9 month − 10-KT 6 month · filed 2019-05-15 | $6.50M derived: sum of 2 quarters · filed 2020-03-26 | $6.90M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $4.77M derived: 10-KT 6 month − 10-Q 3 month · filed 2020-03-26 | $5.18M 10-KT · filed 2020-03-26 | ||
| 2018-09-30 | $404.50K 10-Q · filed 2019-11-13 | |||
| 2014-06-30 | $2.00M 10-K · filed 2015-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |